Skip to content Skip to footer
Insights+ Key Biosimilars Events of November 2023

Insights+ Key Biosimilars Events of November 2023

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency   Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients   During November, Amgen received US FDA approval for Wezlana, biosimilar of ustekinumab &…

Read more

VIEWPOINTS_Jennifer Davidson_2023

Jennifer Davidson Highlights the Data from the Phase 3 QUASAR Induction Study 1

Shots:  Jennifer Davidson, VP, of Medical Affairs Immunology, Johnson & Johnson Innovative Medicine shares insights from the data of the Phase III QUASAR induction study presented at the DDW'23  P-III QUASAR induction study 1 demonstrated positive results in patients who received TREMFYA 200 mg vs Placebo, with most of the patients achieving remission at week…

Read more

VIEWPOINTS_Dr. Jay Backstrom_2023

Dr. Jay Backstrom shares insights from the Phase II TOPAZ trial for the treatment of SMA

Shots:  Dr. Jay Backstrom in an engaging conversation with PharmaShots, shares the highlights of the P-II Topaz trial designed to evaluate the safety and efficacy of apitegromab for the treatment of Spinal Muscle Atrophy (Type 2 & 3)   With the potential to transform care in SMA by directly addressing progressive muscle weakness, apitegromab aims to…

Read more

thoughtspot_John_smith

How Transfer Pumps Enhance Productivity In Pharmaceutical Manufacturing

The pharmaceutical industry is the bedrock of modern medicine. It is responsible for developing, producing, and distributing life-saving medications. Given the critical role of this sector, optimizing productivity without sacrificing quality is of the utmost importance. Using transfer pumps is one element that often goes unnoticed but plays a crucial role in increasing efficiency. These…

Read more

VIEWPOINTS_Eric Halioua_2023

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01

Shots: Eric shared the results from the first immunological results of its PDC-LUNG-101 P-I/II trial with PDC*lung01 which is the company’s cancer vaccine candidate for Non-Small Cell Lung Cancer The results were presented at ESMO-IO 2022 elaborating on the safety, tolerability, immunogenicity, and preliminary clinical activity of the drug candidate The interview shows PDC*line’s vision…

Read more

VIEWPOINTS_Monica Mann_2023

Monica Mann, VP, of Medical Affairs for Global MS and Pipeline at Biogen Shares Insights on New Data on MS Therapies and Digital Health Research

Shots: Monica spoke about the new data from its multiple sclerosis therapies portfolio presented at the 38th ECTRIMS meeting The highlights from the presentation were the safety and efficacy results of Vumerity, patient-reported outcomes from the treatment with Tysabri, and posters highlighting advances in digital health initiatives The interview shows how Biogen develops, and delivers…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]